Literature DB >> 3257773

Monoclonal antipeptide antibodies recognize IL-3 and neutralize its bioactivity in vivo.

H J Ziltener1, I Clark-Lewis, B Fazekas de St Groth, P C Orban, L E Hood, S B Kent, J W Schrader.   

Abstract

Mixtures of synthetic peptides corresponding to segments of murine IL-3 or synthetic IL-3 were used to raise murine mAb. Several mAb able to recognize synthetic IL-3 were obtained, two of which exhibited significant cross-reactivity with native IL-3 as shown by precipitation of biosynthetically 35S-labeled IL-3 and their effectiveness as affinity reagents for the purification of IL-3 from conditioned medium. The amino acid sequence recognized by the two mAb was determined by using synthetic peptide segments of IL-3. In both cases binding of the mAb to synthetic IL-3 was inhibited best with a hexapeptide corresponding to the amino acid residues 130-135 of IL-3, although the mAb differed in other characteristics. Neither mAb neutralized IL-3 bioactivity in vitro. However, we observed that in vivo administration of one mAb abrogated the increase in splenic mast cells and their precursors that normally occurred in mice bearing a s.c. IL-3-producing tumor, WEHI-3B.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257773

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping.

Authors:  P N Redlich; P D Hoeprich; C B Colby; S E Grossberg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

2.  Interleukin-3 protects mice from acute herpes simplex virus infection.

Authors:  W L Chan; H J Ziltener; F Y Liew
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

3.  Structure-function relationships of interleukin-3. An analysis based on the function and binding characteristics of a series of interspecies chimera of gibbon and murine interleukin-3.

Authors:  K Kaushansky; S G Shoemaker; V C Broudy; N L Lin; J V Matous; E M Alderman; J D Aghajanian; P J Szklut; R E VanDyke; M K Pearce
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.